Abstract Proteomics has been constrained by flexibility, high costs, and inconsistent quantification. We present Omni 1000, a quantitative 1000-plex solution powered by nELISA technology—designed for broad, reproducible, and cost-effective protein measurement. Omni 1000 delivers 0.1 pg/mL sensitivity, 99.99% specificity, and dynamic range spanning 3-6 logs. With 10% CV, Omni 1000 ensures precision for discovery and translational applications. Omni 1000 content was developed through a rigorous, data-driven strategy to achieve comprehensive proteome-wide coverage while retaining high-value markers. The foundation is built from two sources: (1) a curated set of Most Valuable Proteins (MVPs)—biomarkers selected heuristically based on prevalence in key signaling pathways, translational research, and validated endpoints; and (2) large-scale, high-plex proteomic datasets with disease-association. To optimize, we applied Minimum Redundancy Maximum Relevance (mRMR) to reduce overlap, reconstruction loss minimization to preserve signal from high-dimensional datasets, and prioritized MVPs. Each iteration was validated against key biological ontologies—achieving 92% MVP coverage, 100% Reactome level 0, 80% Reactome level 1, 100% pharma-relevant KEGG signaling pathways, and 100% MeSH disease classes. For biomarker discovery, Omni 1000 makes large-scale and clinically relevant studies routinely achievable through significant cost-efficiencies and rapid readout with flow cytometry. In a study of plasma biobank samples, use of Omni 1000 successfully demonstrated early insights in detecting active rheumatoid arthritis immune signatures prior to onset of clinical symptoms. In addition, Omni 1000’s high-throughput capabilities were used to support a drug screening platform based on patient-derived tumor organoids. Use of Omni 1000 demonstrated insights on baseline donor heterogeneity and drug compound responses and resistances specific to patient tissue profiles, an effort to advance precision medicine. Together, we demonstrate a novel 1000-plex solution, Omni 1000, with content balancing critical targets and biological breadth, and demonstrate real-world utility through two key applications: early detection of disease and high throughput drug development. Citation Format: Jerid Robinson, Nathaniel Robichaud, Grant Ongo, Kiran Edwardson, Alyssa Rosenbloom, Narges Rashidi, Arya Tavakoli, Jeff Munzar, Milad Dagher, . A scalable, proteome-wide protein profiling platform with absolute quantification of 1000 proteins to power oncologic drug discovery pipelines abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4190.
Robinson et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: